专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004083448A2 MOLECULAR DIFFERENCES BETWEEN SPECIES OF THE M.TUBERCULOSIS COMPLEX 审中-公开
标题翻译： M.TUBERCULOSIS复合物种之间的分子差异
公开(公告)号：WO2004083448A2
公开(公告)日：2004-09-30
申请号：PCT/US2004007668
申请日：2004-03-11
申请人： UNIV LELAND STANFORD JUNIOR , STATENS SERUMINSTITUT , BEHR MARCEL , SMALL PETER , WILSON MICHAEL A , SCHOOLNIK GARY , AAGAARD CLAUS , ROSENKRANDS IDA , WELDINGH KARIN , ANDERSON PETER
发明人： BEHR MARCEL , SMALL PETER , WILSON MICHAEL A , SCHOOLNIK GARY , AAGAARD CLAUS , ROSENKRANDS IDA , WELDINGH KARIN , ANDERSON PETER
IPC分类号： C07K14/35 , C07K16/12 , C12Q20060101 , C12Q1/68 , C12Q
CPC分类号： C07K14/35 , C07K16/1289 , C12Q1/689
摘要： Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tbThe genetic markers can be used for diagnosis of M. tb. infection. One or more antigens provided from the genetic markers can be used in diagnostic assays, e.g. a serological assay.
摘要翻译：在分枝杆菌分离株中鉴定出特异性遗传缺失，包括分离株之间的结核分枝杆菌基因组序列的变异以及BCG中存在的许多缺失与M.tb相比。遗传标记可用于诊断M.bb。感染。从遗传标记提供的一种或多种抗原可用于诊断测定，例如血清学检测。

2. 发明申请

WO0021983A3 TUBERCULOSIS VACCINE AND DIAGNOSTIC REAGENTS BASED ON ANTIGENS FROM THE MYCOBACTERIUM TUBERCULOSIS CELL 审中-公开
标题翻译：基于来自MYCOBACTERIUM TUBERCULOSIS 细胞的抗原的流感疫苗和诊断试剂
公开(公告)号：WO0021983A3
公开(公告)日：2000-11-23
申请号：PCT/DK9900538
申请日：1999-10-08
申请人： STATENS SERUMINSTITUT , ANDERSEN PETER , WELDINGH KARIN , HANSEN CHRISTINA VEGGERBY , FLORIO WALTER , OKKELS LI MEI MENG , SKJOET RIKKE LOUISE VINTHER , ROSENKRANDS IDA
发明人： ANDERSEN PETER , WELDINGH KARIN , HANSEN CHRISTINA VEGGERBY , FLORIO WALTER , OKKELS LI MEI MENG , SKJOET RIKKE LOUISE VINTHER , ROSENKRANDS IDA
IPC分类号： A61K39/00 , C07K14/35 , A61K39/04 , G01N33/569
CPC分类号： C07K14/35 , A61K39/00
摘要： The present invention relates to substantially pure polypeptides, which has a sequence identity of at least 80 % to an amino acid sequence disclosed, or which is a subsequence of at least 6 amino acids thereof, preferably a B- or T-cell epitope of the polypeptides disclosed. The polypeptide or the subsequence thereof has at least one of nine properties. The use of the disclosed polypeptides in medicine is disclosed, preferably as vaccine or diagnostic agents relating to virulent Mycobacterium . The invention further relates to the nucleotide sequences disclosed and the nucleotide sequences encoding the disclosed polypeptides. Medical and non-medical use of the nucleotide sequences is disclosed.
摘要翻译：本发明涉及基本上纯的多肽，其与所公开的氨基酸序列具有至少80％的序列同一性，或者是其至少6个氨基酸，优选B细胞或T-细胞表位的亚序列多肽披露。多肽或其亚序列具有九个性质中的至少一个。公开了所公开的多肽在药物中的用途，优选作为与毒性分枝杆菌有关的疫苗或诊断剂。本发明还涉及所公开的核苷酸序列和编码公开的多肽的核苷酸序列。披露了核苷酸序列的医学和非医学用途。

3. 发明申请

WO2005004911A3 ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES 审中-公开
标题翻译：用于免疫组合物和疫苗的脂质体和肌醇脂的补充剂组合
公开(公告)号：WO2005004911A3
公开(公告)日：2005-02-17
申请号：PCT/DK2004000488
申请日：2004-07-07
申请人： STATENS SERUMINSTITUT , AGGER ELSE MARIE , ANDERSEN PETER , OLSEN ANJA , ROSENKRANDS IDA
发明人： AGGER ELSE MARIE , ANDERSEN PETER , OLSEN ANJA , ROSENKRANDS IDA
IPC分类号： A61K39/04 , A61P31/06 , A61K39/39
CPC分类号： A61K39/04 , A61K2039/55555 , A61K2039/55594
摘要： The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from .The total lipid extract contains both apolar 1ipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.
摘要翻译：本发明提供了由表面活性剂，即二甲基十二烷基溴化铵/氯化物（DDA）和脂质提取物的组合组成的疫苗佐剂。本发明提供了由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）组合的疫苗佐剂）和来自<本发明的脂质提取物提供由表面活性剂组合的疫苗佐剂，即二甲基十八烷基溴化铵/氯化物（DDA）和牛分枝杆菌的脂质提取物。本发明提供由表面活性剂，即二甲基十八烷基溴化铵/氯化物（DDA）和来自牛分枝杆菌的脂质提取物的组合组成的疫苗佐剂。本发明提供由表面活性剂组合的疫苗佐剂，即二甲基十八烷基溴化铵/ 氯化物（DDA）和牛分枝杆菌BCG的脂质提取物本发明提供了由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和牛分枝杆菌BCG的脂质提取物的组合组成的疫苗佐剂。本发明提供了一种疫苗由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和牛分枝杆菌BCG的脂质提取物的组合组成的佐剂。本发明提供了由表面活性剂，即二甲基十八烷基溴化铵/氯化物（DDA）和牛分枝杆菌BCG的脂质提取物的组合组成的疫苗佐剂。本发明提供一种由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和牛分枝杆菌BCGI的脂质提取物的组合组成的疫苗佐剂。总脂质提取物含有非极性脂质，极性脂质和脂质发现非极性脂质诱导最强大的免疫应答的中间极性。总脂质可以用氯仿/甲醇萃取，并在加入表面活性剂之前再溶解在水中。这种制剂可用于在哺乳动物中诱导突出的细胞介导的免疫应答，以抵抗病原体，或作为癌症的治疗。

4. 发明申请

WO2004006952A2 THERAPEUTIC TB VACCINE 审中-公开
标题翻译：治疗TB疫苗
公开(公告)号：WO2004006952A2
公开(公告)日：2004-01-22
申请号：PCT/DK0300477
申请日：2003-07-08
申请人： STATENS SERUMINSTITUT , ANDERSEN PETER , ROSENKRANDS IDA , STRYHN ANETTE
发明人： ANDERSEN PETER , ROSENKRANDS IDA , STRYHN ANETTE
IPC分类号： A61K39/02 , A61K39/04 , A61P31/06 , C07K14/35 , C12Q1/04
CPC分类号： C07K14/35 , A61K39/04 , A61K2039/55572 , A61K2300/00
摘要： The present invention is based on a number of M.tuberculosis derived proteins and protein fragments which are induced during the latent stage of infection characterized by low oxygen tension in the microenvironment of the infecting TB-bacteria. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as therapeutic vaccines and diagnostic reagents.
摘要翻译：本发明基于在感染潜伏期期间诱导的结核分枝杆菌来源的蛋白质和蛋白质片段，其特征在于感染TB细菌的微环境中的低氧张力。本发明涉及这些多肽，其免疫活性片段和编码它们的免疫学组合物如治疗性疫苗和诊断试剂的基因的用途。

5. 发明申请

WO2006002642A3 COMPOSITIONS AND METHODS FOR STABILIZING LIPID BASED ADJUVANT FORMULATIONS USING GLYCOLIPIDS 审中-公开
标题翻译：用甘油脂稳定脂质基辅助制剂的组合物和方法
公开(公告)号：WO2006002642A3
公开(公告)日：2006-05-18
申请号：PCT/DK2005000467
申请日：2005-07-05
申请人： STATENS SERUMINSTITUT , DAVIDSEN JESPER , ROSENKRANDS IDA , ANDERSEN PETER
发明人： DAVIDSEN JESPER , ROSENKRANDS IDA , ANDERSEN PETER
IPC分类号： A61K9/127 , A61K39/015 , A61K39/04 , A61K39/118
CPC分类号： A61K39/04 , A61K9/1272 , A61K2039/55555
摘要： The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.
摘要翻译：本发明涉及物理稳定的脂质体制剂。具体而言，本发明涉及通过将糖脂掺入脂质体中来使阳离子脂质体空间稳定化。稳定的脂质体可以用作抗原组分的佐剂或作为药物递送系统。具体地说，本发明涉及在含水介质中用佐剂进行免疫的疫苗，其中最终产品是稳定的。

6. 发明申请

WO2005004911B1 ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES 审中-公开
标题翻译：脂质体和细菌脂质的辅助组合用于免疫组合物和疫苗
公开(公告)号：WO2005004911B1
公开(公告)日：2005-03-17
申请号：PCT/DK2004000488
申请日：2004-07-07
申请人： STATENS SERUMINSTITUT , AGGER ELSE MARIE , ANDERSEN PETER , OLSEN ANJA , ROSENKRANDS IDA
发明人： AGGER ELSE MARIE , ANDERSEN PETER , OLSEN ANJA , ROSENKRANDS IDA
IPC分类号： A61K39/04 , A61P31/06 , A61K39/39
CPC分类号： A61K39/04 , A61K2039/55555 , A61K2039/55594
摘要： The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from .The total lipid extract contains both apolar 1ipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.
摘要翻译：本发明提供了由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和脂质提取物的组合组成的疫苗佐剂。本发明提供了一种疫苗佐剂，其由表面活性剂即二甲基十八烷基溴化铵/氯化物）和本发明的脂质提取物。本发明提供了由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和来自牛分枝杆菌的脂质提取物的组合组成的疫苗佐剂。本发明提供了由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和来自牛分枝杆菌的脂质提取物的组合组成的疫苗佐剂。本发明提供了一种疫苗佐剂，其由表面活性剂即二甲基十八烷基溴化铵/ （DDA）和来自牛分枝杆菌BCG的脂质提取物本发明提供了由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和来自牛分枝杆菌BCG的脂质提取物的组合组成的疫苗佐剂。本发明提供了一种接种佐剂，其由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和来自牛分枝杆菌BCG的脂质提取物的组合组成。本发明提供了由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和来自牛分枝杆菌BCG的脂质提取物的组合组成的疫苗佐剂。本发明提供了由表面活性剂即二甲基十八烷基溴化铵/氯化物（DDA）和来自牛分枝杆菌BCG I的脂质提取物的组合组成的疫苗佐剂。总脂质提取物含有非极性脂质，极性脂质和脂质中极性的非极性脂质被发现诱导最强大的免疫反应。在添加表面活性剂之前，总脂质可以用氯仿/甲醇提取并且重新溶解在水中。该制剂可用于诱导哺乳动物中显着的细胞介导的免疫应答以对抗病原体或作为癌症治疗。

7. 发明申请

WO2014063704A3 M. TUBERCULOSIS VACCINES 审中-公开
标题翻译：结核分枝杆菌疫苗
公开(公告)号：WO2014063704A3
公开(公告)日：2014-06-19
申请号：PCT/DK2013000070
申请日：2013-10-18
申请人： STATENS SERUMINSTITUT
发明人： AAGAARD CLAUS , ROSENKRANDS IDA , HOANG TRUC THI KIM THANH , ANDERSEN PETER
IPC分类号： C07K14/35 , A61K38/00 , A61K39/00
CPC分类号： A61K39/04 , A61K2039/55555 , C07K14/35 , C07K2319/00 , C07K2319/40
摘要： The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1 ) which are among the most immunodominant M. tuberculosis (MTB) antigens.
摘要翻译：本发明涉及融合蛋白，抗原混合物和免疫组合物，例如抗有毒分枝杆菌引起的感染的疫苗，由非结核分枝杆菌，非洲分枝杆菌，牛分枝杆菌，微小分枝杆菌，卡氏分枝杆菌，pinnipedi分枝杆菌或真菌分枝杆菌。融合蛋白或抗原混合物基于ESX分泌或相关蛋白，例如，由ESAT-6分泌系统1（ESX-1）分泌的蛋白质是最具免疫优势的结核分枝杆菌（MTB）抗原。

8. 发明申请

WO2015090322A8 DIAGNOSTIC REAGENTS FOR IMPROVED IN VIVO OR IN VITRO CELL-MEDIATED IMMUNOLOGICAL DIAGNOSIS OF TUBERCULOSIS 审中-公开
标题翻译：用于改善体内或体外细胞介导的结核病免疫诊断的诊断试剂
公开(公告)号：WO2015090322A8
公开(公告)日：2016-07-21
申请号：PCT/DK2014000062
申请日：2014-12-15
申请人： STATENS SERUMINSTITUT
发明人： AAGAARD CLAUS , HOFF SØREN TETENS , ROSENKRANDS IDA , AGGER ELSE MARIE , ANDERSEN PETER LAWÆTZ
IPC分类号： G01N33/569
CPC分类号： G01N33/5695 , G01N2469/20
摘要： The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
摘要翻译：本发明公开了具有增强的特异性和灵敏度用于检测结核病的体外和体内诊断方法。本发明的诊断剂可以替代以前的混合物/鸡尾酒/包含ESAT-6但包括ESAT6的抗原库，进一步改进了诊断。

9. 发明申请

WO2014063704A8 M. TUBERCULOSIS VACCINES 审中-公开
公开(公告)号：WO2014063704A8
公开(公告)日：2015-07-30
申请号：PCT/DK2013000070
申请日：2013-10-18
申请人： STATENS SERUMINSTITUT
发明人： AAGAARD CLAUS , ROSENKRANDS IDA , HOANG TRUC THI KIM THANH , ANDERSEN PETER
IPC分类号： C07K14/35 , A61K38/00 , A61K39/00
CPC分类号： A61K39/04 , A61K2039/55555 , C07K14/35 , C07K2319/00 , C07K2319/40
摘要： The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1 ) which are among the most immunodominant M. tuberculosis (MTB) antigens.
摘要翻译：本发明涉及融合蛋白，抗原鸡尾酒和免疫组合物，例如针对由致病性分枝杆菌引起的感染的疫苗，例如，结核分枝杆菌，非洲分枝杆菌，牛分枝杆菌，分枝杆菌，分枝杆菌，分枝杆菌或粘液分枝杆菌。融合蛋白或抗原鸡尾酒基于ESX分泌或相关蛋白，例如由最具免疫优势的结核分枝杆菌（MTB）抗原组成的ESAT-6分泌系统1（ESX-1）分泌的蛋白质。

10. 发明专利

HRP20210933T1 DIJAGNOSTIČKI REAGENSI ZA UNAPRIJEĐENU IN VIVO ILI IN VITRO STANIČNO-POSREDOVANU IMUNOLOŠKU DIJAGNOZU TUBERKULOZE 未知
公开(公告)号：HRP20210933T1
公开(公告)日：2021-09-03
申请号：HRP20210933
申请日：2021-06-10
申请人： STATENS SERUMINSTITUT
发明人： AAGAARD CLAUS , HOFF SØREN TETENS , ROSENKRANDS IDA , AGGER ELSE MARIE , ANDERSEN PETER LAWÆTZ
IPC分类号： G01N33/569

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式